AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 91 min read$AXSM

TABUTEAU HERRIOT sold $12.0M of AXSM

TABUTEAU HERRIOT (Chief Executive Officer) sold 49,670 shares of Axsome Therapeutics, Inc. (AXSM) at $241.01 ($11.97M total) on 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TABUTEAU HERRIOT
Published Jun 9, 2026, 9:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AXSM
Neutral
medium confidence
Mentioned
$AXSM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXSMNeutralLow
01

Why it matters

The main tradable takeaway is sentiment/positioning optics from a sizable insider sale; however, the 10b5-1 designation suggests the timing was predetermined.

02

Market read

Material insider selling disclosed today, but pre-arranged 10b5-1 reduces the likelihood of a new negative fundamental signal.

03

What to watch

The filing doesn’t disclose intent beyond the plan; traders should avoid extrapolating fundamentals from a single scheduled sale without corroborating news (trial/regulatory/financing).

Relevance 6/10Novelty 8/10Timing: filed today (2026-06-09)

Background

The article is an SEC Form 4 insider transaction disclosure (open-market sale) by Axsome’s CEO/10% owner.

Company-level read

Ticker impact

$AXSMNeutralMedium confidence
Context

Axsome CEO TABUTEAU HERRIOT sold 49,670 shares for ~$11.97M via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Near-term drift risk (sell-overhang optics), but likely limited fundamental impact given 10b5-1 pre-arrangement.

Evidence & confidence

The filing is primary-source and material in size, yet it explicitly states a pre-arranged 10b5-1 plan, which typically dampens inference about new negative information.

Market effects

Sector

No direct sector read-through; this is company-specific insider liquidity/positioning rather than a clinical/regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is executed under a pre-arranged 10b5-1 plan, it may reflect routine diversification rather than bearish expectations.

Key entities

  • issuer
    Axsome Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    TABUTEAU HERRIOT

    CEO, officer/director, and 10% owner who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AXSM insider trading history →

Related articles

AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min
AUG 11
$AXSMMed

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics (AXSM) reported Q2 updates on AUVELITY, SYMBRAVO, and SUNOSI, including gross-to-net discounts and prescription growth. AUVELITY was launched for Alzheimer’s agitation, with total prescriptions about 266,000. SYMBRAVO prescriptions rose to about 23,500. FDA accepted AXS-12 NDA with a May 1, 2027 target date. Costs and expenses were also detailed.

yahoo.com6 min